Key points from article :
Hevolution Foundation invested $20 million in Aeovian Pharmaceuticals to develop therapies for diseases of aging.
The funding will help Aeovian complete clinical trials for a treatment for tuberous sclerosis complex (TSC) epilepsy.
Aeovian's treatment focuses on mTORC1, a biological pathway linked to aging.
AV078,CNS penetrant selective mTORC1 inhibitor, has the potential to be transformative for patients with TSC refractory epilepsy.
Investment to address major unmet medical needs including TSC refractory epilepsy, neurological diseases and prevalent aging diseases.
Hevolution's CEO Mehmood Khan says funding scientific research on aging is a key strategy but investments in longevity companies will also be announced soon.
This investment is part of Hevolution's $250 million commitment to healthspan research.
